Welcome to our dedicated page for Oragenics SEC filings (Ticker: OGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Oragenics, Inc. (OGEN) SEC filings page provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. Oragenics is a clinical-stage biotechnology company focused on intranasal therapeutics for neurological disorders, led by its concussion and mild traumatic brain injury candidate ONP-002. Through its filings, the company discloses material agreements, financing transactions, governance changes, and details of its development strategy.
Investors can review current reports on Form 8-K to see how Oragenics documents key events such as public offerings of Series H Convertible Preferred Stock and Warrants, the entry into material agreements with its placement agent, updates on NYSE American listing compliance, settlements of disputes, and appointments and compensation of directors and executive officers. These 8-K filings also frequently incorporate press releases that summarize shareholder updates, clinical progress, and strategic partnerships.
Registration statements on Form S-1 and related amendments outline the structure and terms of Oragenics’ securities offerings, including the rights of holders of Series H preferred stock, conversion features into common stock, dividend provisions, and potential dilution. These documents also describe the company’s status as a smaller reporting company, its principal executive offices in Sarasota, Florida, and its focus on nasal delivery of pharmaceutical medications in neurology and infectious diseases.
Through this page, users can also locate exhibits referenced in filings, such as equity incentive plans, stock option award forms, at-the-market sales agreements, and key collaboration or license agreements. Together, these materials provide a detailed view of Oragenics’ capital structure, governance framework, and contractual relationships that support its ONP-002 program and intranasal platform.
Stock Titan enhances these filings with AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly understand the implications of new 8-Ks, S-1 registrations, and other submissions. Real-time updates from EDGAR, combined with structured access to forms related to financings, governance, and listing compliance, allow investors to follow how Oragenics is funding and governing its clinical-stage operations over time.
Oragenics, Inc. reported an equity award to its CEO and CFO, Janet Huffman. On 12/11/2025 she was granted an employee stock option to buy 250,000 shares of Oragenics common stock at an exercise price of $0.93 per share under the Company's 2021 Equity Incentive Plan, as amended.
One third of the options vest on the first anniversary of the grant date, with the remaining two thirds vesting in equal annual installments on the second and third anniversaries, provided she continues to perform services for the company through each vesting date. The options are scheduled to expire on 12/11/2035, and the exercise price was set at the closing price of the common stock on the grant date.
Oragenics Inc. reported that director Natasha Giordano received two stock option awards under the company’s 2021 Equity Incentive Plan on December 11, 2025. One non-employee director option covers 38,320 shares of common stock at an exercise price of $1.03, granted as an initial equity award upon her appointment to the board, and it vests immediately. A second option covers 125,000 shares at an exercise price of $0.93, also under the non-employee director compensation program, and it vests immediately as well. Both option grants are exercisable from December 11, 2025 and expire on December 11, 2035, and are held directly.
Oragenics Inc. director Fred Telling reported a small sale of company stock and a new stock option grant. On 12/12/2025, he sold 210 shares of common stock at a weighted average price of $0.9446 per share, leaving him with 34,538 shares of Oragenics common stock held directly.
On 12/11/2025, he received a non-employee director option award for 125,000 shares of Oragenics common stock under the company’s 2021 Equity Incentive Plan. The options have an exercise price of $0.93 per share, vest immediately on the grant date, and are scheduled to expire on 12/11/2035.
Oragenics Inc (OGEN) reported a grant of non-employee director stock options to director John Gandolfo. On 12/11/2025 he received options to purchase 125,000 shares of common stock at an exercise price of $ 0.93, with an expiration date of 12/11/2035.
The award was made under Oragenics' 2021 Equity Incentive Plan, as amended, pursuant to its non-employee director compensation program. The options vest immediately, and Gandolfo beneficially holds 125,000 derivative securities directly following this transaction.
Oragenics director Alan Dunton reported receiving an award of 125,000 options to buy the company’s common stock at an exercise price of $0.93 per share on 12/11/2025.
The options were granted under the company’s 2021 Equity Incentive Plan, as amended, pursuant to its non-employee director compensation program. They vest immediately, are exercisable starting 12/11/2025, and expire on 12/11/2035. Following this grant, 125,000 derivative securities are beneficially owned directly.
Oragenics Inc reported that director Robert Koski received a grant of stock options on 12/11/2025 under the company's 2021 Equity Incentive Plan, as amended, pursuant to its non-employee director compensation program. The option covers 125,000 shares of common stock at an exercise price of $0.93 per share, equal to the closing price on the grant date. The options vest immediately, are exercisable starting 12/11/2025, and expire on 12/11/2035. Following this award, Koski beneficially owns 125,000 stock options directly.
Oragenics Inc. reported that director Charles Pope received an award of stock options as part of the company’s non-employee director compensation program. On 12/11/2025 he was granted options to buy 125,000 shares of common stock at an exercise price of $0.93 per share under the company’s 2021 Equity Incentive Plan, as amended.
The options vest immediately, making them fully exercisable from the grant date, and they expire on 12/11/2035. After this grant, Pope beneficially owns 125,000 derivative securities directly, each representing the right to purchase one share of Oragenics common stock.
Oragenics, Inc. updated compensation for its leadership. The board increased Chief Executive Officer Janet Huffman’s annual base salary by five percent from $325,000 to $341,250, effective January 1, 2026, and awarded her a cash bonus of $110,500 based on performance under the existing compensation program.
The board also granted Huffman stock options to purchase 250,000 shares of common stock at an exercise price of $0.93 per share, vesting in equal annual installments over three years, with earlier vesting upon a change in control. Each non-employee director received options for 125,000 shares at $0.93 per share that vested immediately, and director Natasha Giordano received an additional onboarding stock option award valued at $30,000 when she joined the board.
A holder of OGEN common stock has filed a notice of proposed sale under Rule 144. The filing covers the planned sale of 210 shares of common stock through Goldman Sachs & Co. LLC on the NYSE, with an aggregate market value of 191.94. The shares relate to an issuer that had 4,168,223 shares outstanding at the time stated. The seller acquired 171 shares as restricted stock units on 06/17/2022 and 39 shares as restricted stock units on 11/20/2020, both described as compensation from the issuer.
Oragenics, Inc. filed a current report to note that it has issued a new press release for shareholders. On November 12, 2025, the company released an update describing recent developments that took place during the third quarter of 2025 and shortly afterward. The report states that this press release is being furnished as an exhibit and incorporated by reference, directing readers to that document for the detailed business and operational update.